December 29, 2014 3:40 AM ET

Biotechnology

Company Overview of Accentia Biopharmaceuticals, Inc.

Company Overview

Accentia Biopharmaceuticals, Inc., a biotechnology company, primarily discovers, develops, and commercializes immunotherapies to treat autoimmune related diseases and cancer in the United States. The company develops Cyrevia as a system of care for various autoimmune diseases; BiovaxID as a personalized therapeutic cancer vaccine to treat non-Hodgkin’s lymphoma, follicular lymphoma, mantle cell lymphoma, and other B-cell cancers; and SinuNasal lavage system as a medical device for chronic sinusitis. It also manufactures and sells a range of cell culture systems used for the production cell culture products, including HF Primer, a cell culture system for producing small, research, and develop...

324 South Hyde Park Avenue

Suite 350

Tampa, FL 33606

United States

Founded in 2002

51 Employees

Phone:

813-864-2554

Fax:

813-258-6912

Key Executives for Accentia Biopharmaceuticals, Inc.

Chief Scientific Officer
Age: 37
Total Annual Compensation: $185.0K
Compensation as of Fiscal Year 2012.

Accentia Biopharmaceuticals, Inc. Key Developments

Accentia Biopharmaceuticals, Inc. announced delayed 10-Q filing

On 08/15/2013, Accentia Biopharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Shapiro Haber & Urmy LLP and Liggio Benrubi PA Files Class Action Lawsuit Against Accentia Biopharmaceuticals, Inc. and Officers and Directors of Accentia and Biovest International, Inc

Shapiro Haber & Urmy LLP and Liggio Benrubi PA filed a class action on July 26, 2013 against Accentia Biopharmaceuticals, Inc. (ABPI) and certain officers and directors of Accentia and Biovest International, Inc., a majority-owned subsidiary of Accentia, for violations of federal securities laws. The case has been filed in the United States District Court for the Middle District of Florida and is entitled Hill v. Accentia Biopharmaceuticals, et al., C.A. No. 13-cv-01945. The Complaint alleges that the FDA informed Biovest that the results of a Phase III clinical trial for BiovaxID, a potential vaccine for the treatment of non-Hodgkin's lymphoma, did not support an application for approval of BiovaxID. Despite this information, Defendants made numerous statements in press releases and securities filings that gave the misleading impression that the trial results were statistically significant and that Biovest was on track to obtain FDA approval. The Complaint alleges that these misstatements and omissions by Defendants misrepresented and/or omitted material facts to the investing public, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act. The class action is brought on behalf of all persons and entities who purchased common stock of either Accentia or Biovest from July 26, 2008 through August 14, 2012.

Accentia Biopharmaceuticals, Inc. announced delayed 10-Q filing

On 05/15/2013, Accentia Biopharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Similar Private Companies By Industry

Company Name Region
BioMarck Pharmaceuticals, Ltd. United States
D. E. Shaw Research, LLC United States
Siva Therapeutics Inc. United States
Orthonics Inc. United States
Conkwest, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Accentia Biopharmaceuticals, Inc., please visit www.accentia.net. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.